CASR and Hypocalcemia: However, clinical use of CIN is limited because it induces clinically significant hypocalcemia [12], likely resulting from both suppressed renal calcium reabsorption and calcitonin-mediated inhibition of bone resorption via CaSR activation in thyroid C-cells [13].